Immuneering Corporation
NASDAQ:IMRX
Overview | Financials
Company Name | Immuneering Corporation |
Symbol | IMRX |
Currency | USD |
Price | 2.33 |
Market Cap | 72,347,432 |
Dividend Yield | 0% |
52-week-range | 1 - 7.88 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. |
Website | https://immuneering.com |
An error occurred while fetching data.
About Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD